Galectin 3 and incident atrial fibrillation in the community
Department of Medicine, Division of Cardiovascular Medicine; Meyers Primary Care Institute
Aged; Atrial Fibrillation; Biological Markers; Cardiomyopathies; Disease Progression; Echocardiography; Enzyme-Linked Immunosorbent Assay; Female; Fibrosis; Follow-Up Studies; Galectin 3; Heart Atria; Humans; Incidence; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Risk Factors; United States
Cardiology | Cardiovascular Diseases | Clinical Epidemiology | Translational Medical Research
BACKGROUND: Galectin 3 (Gal-3) is a potential mediator of cardiac fibrosis, and Gal-3 concentrations predict incident heart failure. The same mechanisms that lead to cardiac fibrosis in heart failure may influence development of atrial fibrosis and atrial fibrillation (AF). We examined the association of Gal-3 and incident AF in the community.
METHODS: Plasma Gal-3 concentrations were measured in 3,306 participants of the Framingham Offspring cohort who attended the sixth examination cycle (1995-1998, mean age 58 years, 54% women). Cox proportional hazards regression models were used to assess the association of baseline Gal-3 concentrations and incident AF.
RESULTS: Over a median follow-up period of 10 years, 250 participants developed incident AF. Crude incidence rates of AF by increasing sex-specific Gal-3 quartiles were 3.7%, 5.9%, 9.1%, and 11.5% (log-rank test P < .0001). In age- and sex-adjusted analyses, each 1-SD increase in loge-Gal-3 was associated with a 19% increased hazard of incident AF (hazard ratio 1.19, 95% CI 1.05-1.36, P = .009). This association was not significant after adjustment for traditional clinical AF risk factors (hazard ratio 1.12, 95% CI 0.98-1.28, P = .10).
CONCLUSION: Higher circulating Gal-3 concentrations were associated with increased risk of developing AF over the subsequent 10 years in age- and sex-adjusted analyses but not after accounting for other traditional clinical AF risk factors. Our results do not support a role for Gal-3 in AF risk prediction. Further studies are needed to evaluate whether Gal-3 plays a role in the development of AF substrate similar to HF.
DOI of Published Version
Ho JE, Yin X, Levy D, Vasan RS, Magnani JW, Ellinor PT, McManus DD, Lubitz SA, Larson MG, Benjamin EJ. Galectin 3 and incident atrial fibrillation in the community. Am Heart J. 2014 May;167(5):729-34.e1. doi: 10.1016/j.ahj.2014.02.009.
American heart journal
Ho JE, Yin X, Levy D, Vasan RS, Magnani JW, Ellinor PT, McManus DD, Lubitz SA, Larson MG, Benjamin EJ. (2014). Galectin 3 and incident atrial fibrillation in the community. UMass Center for Clinical and Translational Science Supported Publications. https://doi.org/10.1016/j.ahj.2014.02.009. Retrieved from https://escholarship.umassmed.edu/umccts_pubs/17